News|Articles|November 21, 2026

DermNexus 2026 Day 1 Recap: Emerging Therapies and Clinical Insights

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • Mechanism-based prescribing increasingly requires fluency in OX40, JAK, TYK2, and BTK biology to rationalize sequencing after inadequate response to established therapies.
  • Safety counseling for oral JAK inhibitors should be individualized and explicit, integrating infection, cardiovascular, malignancy, and thrombosis risks into shared decision-making.
SHOW MORE

DermNexus 2026 Day 1 explored emerging therapies, immune pathways, and treatment advances in CSU, atopic dermatitis, vitiligo, and HS.

The first day of DermNexus 2026: The Inflammatory Disease and Innovations Congress for NP/PAs brought dermatology nurse practitioners and physician assistants together in Scottsdale, Arizona, on November 20 to examine the rapidly evolving management of inflammatory skin diseases. From emerging immunologic targets and nonsteroidal therapies to the challenges of diagnosing and managing complex chronic conditions, the educational program emphasized translating scientific advances into practical clinical decision-making.

The meeting opened with remarks from conference chair Lauren Miller, MPAS, PA-C, of Surgical Dermatology Group in Gadsden, Alabama, before transitioning into educational sessions addressing treatment mechanisms, chronic spontaneous urticaria (CSU), atopic dermatitis (AD), vitiligo, alopecia areata (AA), and hidradenitis suppurativa (HS).

Across the day's presentations, a central theme emerged: As treatment options become increasingly targeted, clinicians must integrate an understanding of disease mechanisms with individual patient characteristics, treatment histories, and long-term management goals.

Decoding Emerging Mechanisms of Action

The first educational session, "Alphabet Soup: Making Sense of New MOAs," examined the immunologic pathways driving inflammatory skin diseases and the therapeutic approaches designed to interrupt them.

Faculty explored OX40, Janus kinase (JAK), tyrosine kinase 2 (TYK2), and Bruton tyrosine kinase (BTK), highlighting their distinct roles in immune activation and intracellular signaling.

Daniel Butler, MD, described OX40 as an early component of T-cell activation, explaining how the pathway helps initiate and sustain inflammatory responses.

"It's helpful to know that OX40 is sort of the starter. It's the priming molecule that can help start your immune system," Butler said.

The discussion also addressed JAK inhibitors, which influence multiple cytokine-signaling pathways and have demonstrated efficacy across several immune-mediated dermatologic conditions.

However, faculty emphasized the importance of contextualizing safety concerns, including serious infections, cardiovascular events, malignancy, and thrombosis, according to individual patient risk factors.

"Do I talk about cardiovascular disease in oral JAK patients? Absolutely, because I'm not going to hide anything," Butler said.

The session also explored TYK2 selectivity and the role of BTK inhibition in mast-cell–mediated disease.

Clinical cases involving refractory CSU and biologic-experienced psoriatic arthritis illustrated how an understanding of immune signaling can inform treatment selection when patients experience inadequate responses to established therapies.

Emerging Targets and Nonsteroidal Therapies

The second session, "Spotlight on Targets in Dermatologic Diseases," featured Butler; Robert J. Casquejo, PA-C; and David Seiter, FNP-C, DCNP, of Epiphany Dermatology.

The faculty examined advances in CSU management and the expanding range of nonsteroidal topical therapies available for inflammatory skin diseases.

Discussions of CSU focused on the limitations of antihistamine-based treatment and the growing interest in targeting mast-cell activation, type 2 inflammation, and neuroimmune signaling.

Therapeutic approaches included anti-immunoglobulin E treatment with omalizumab, interleukin-4 and interleukin-13 pathway inhibition with dupilumab, and BTK inhibition with remibrutinib.

The presenters also examined investigational approaches targeting additional pathways, including IL-31 and KIT, as researchers continue exploring the mechanisms contributing to persistent itching and wheals.

The session then transitioned to nonsteroidal topical treatments, including JAK inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and aryl hydrocarbon receptor (AhR) agonists.

Ruxolitinib and delgocitinib were discussed as topical JAK inhibitors, while crisaborole, roflumilast, and difamilast were reviewed as examples of PDE4 inhibition.

Faculty also highlighted tapinarof, an AhR agonist that modulates inflammatory signaling while supporting skin-barrier protein expression and antioxidant activity.

Across these therapeutic classes, the discussion emphasized the importance of selecting treatments according to disease presentation, anatomical location, tolerability, and patient preferences.

Optimizing Pediatric Atopic Dermatitis Management

The morning program also featured a continuing education symposium titled "Pediatric Atopic Dermatitis: Role of Advanced Topical Therapies in Optimizing Management."

The symposium focused on the evolving role of advanced topical treatments in pediatric AD, a condition that can present substantial challenges for patients and caregivers because of chronic inflammation, pruritus, and the need for ongoing disease management.

As nonsteroidal topical options continue to expand, treatment selection increasingly involves considerations beyond disease severity alone, including age-specific indications, anatomical location, tolerability, and the practicality of long-term treatment regimens.

The session's focus on advanced topical therapies complemented the earlier discussions of emerging mechanisms of action, reinforcing the importance of individualized approaches to managing inflammatory skin disease across different patient populations.

Examining Shared Immune Pathways in Vitiligo and Alopecia Areata

The afternoon educational program continued with "Cross Talk: Immune Pathways in Vitiligo & Alopecia Areata."

The session focused on the immunologic connections between 2 autoimmune dermatologic conditions characterized by distinct clinical manifestations but overlapping inflammatory mechanisms.

Both vitiligo and AA involve immune-mediated processes that disrupt normal skin or hair follicle function, making them important areas of investigation for targeted immunomodulatory therapies.

In vitiligo, interferon gamma–associated signaling and downstream chemokines contribute to the immune response directed against melanocytes. In AA, inflammatory pathways involving cytotoxic T cells and cytokine signaling contribute to hair follicle dysfunction.

These mechanisms have supported growing interest in JAK inhibition as a treatment strategy for both conditions.

The session's focus on shared immune pathways reflected a broader theme of the meeting: Understanding the biological mechanisms underlying dermatologic diseases may help clinicians recognize therapeutic opportunities across conditions that appear clinically different.

Recognizing the Hidden Burden of Hidradenitis Suppurativa

Later in the afternoon, the session "Hidden Disease: Recognizing, Treating & Supporting Patients with HS" shifted attention toward the challenges of identifying and managing a chronic inflammatory condition frequently associated with delayed diagnosis and substantial patient burden.

HS is characterized by recurrent inflammatory nodules, abscesses, draining tunnels, and scarring, often affecting intertriginous areas.

Beyond its physical manifestations, the disease can have significant effects on pain, mobility, quality of life, and psychosocial well-being.

The session's emphasis on recognition, treatment, and patient support highlighted the need for comprehensive approaches to HS care.

As the therapeutic landscape continues to evolve, clinicians must consider disease severity, inflammatory activity, structural damage, comorbidities, and patient-reported outcomes when developing management strategies.

The topic also underscored the importance of timely diagnosis, patient education, and coordinated care in reducing the long-term burden of chronic inflammatory disease.

Connecting Clinical Education With Practical Application

The first day concluded with a 90-minute PODS session, following an educational program that addressed both emerging therapeutic science and the practical challenges of inflammatory skin disease management.

The day's agenda also included non-continuing education product theaters focused on the IL-31 neuroimmune pathway and a treatment option for moderate to severe AD.

Together, these activities reflected the breadth of topics relevant to dermatology NPs and PAs, from understanding intracellular signaling and emerging treatment mechanisms to recognizing disease burden and supporting patients through long-term treatment decisions.

The program emphasized that advances in dermatologic therapeutics require more than familiarity with new medications. Effective clinical application also depends on understanding treatment limitations, evaluating patient-specific risks, and communicating realistic expectations.

Looking Ahead to Day 2

The meeting continues November 21 with an expanded focus on the systemic and multidisciplinary dimensions of inflammatory skin disease.

Scheduled sessions include "Beyond the Skin: How Treating Inflammation Improves Comorbidities," examining the rheumatologic connections of inflammatory disease, and "Red Flags in the Exam Room: Systemic Clues Not to Miss," exploring gastrointestinal associations and clinical warning signs.

Additional presentations will address the overlap between dermatology and allergy, as well as the psychological burden of chronic skin disease.

The second day will conclude with additional PODS programming and closing remarks from Miller.

As DermNexus 2026 moves into its second day, the opening program has established a foundation centered on increasingly targeted therapies, shared inflammatory pathways, and the importance of comprehensive patient care.

From novel mechanisms of action to the recognition of often-overlooked disease burden, Day 1 highlighted the evolving responsibilities of dermatology NPs and PAs as treatment options expand and clinical decision-making becomes increasingly individualized.

References

  1. Guttman-Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024;191(4):488-496.
    https://doi.org/10.1093/bjd/ljae230
  2. Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994.
    https://doi.org/10.1056/NEJMoa2408792
  3. Ingram JR, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009-1017.
    https://doi.org/10.1111/bjd.17537

Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.